CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
…, CR Flowers, S Tummala, JL Ramdial… - Blood …, 2021 - ashpublications.org
The Endothelial Activation and Stress Index (EASIX) score, defined as [(creatinine × lactate
dehydrogenase [LDH])/platelets], is a marker of endothelial activation that has been …
dehydrogenase [LDH])/platelets], is a marker of endothelial activation that has been …
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
…, MA Rodriguez, EJ Shpall, JL Ramdial… - Blood …, 2023 - ashpublications.org
A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell
Lymphoma Page 1 American Society of Hematology 2021 L Street NW, Suite 900, Washington, …
Lymphoma Page 1 American Society of Hematology 2021 L Street NW, Suite 900, Washington, …
[HTML][HTML] High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients
…, F Martinez, J Song, PF Thall, JL Ramdial… - Frontiers in …, 2021 - frontiersin.org
Background COVID-19 Convalescent plasma (CCP) is safe and effective, particularly if
given at an early stage of the disease. Our study aimed to identify an association between …
given at an early stage of the disease. Our study aimed to identify an association between …
Innate cell engager AFM13 combined with preactivated and expanded cord blood-derived NK cells for patients with double refractory CD30+ lymphoma
…, D Esqueda, R Bassett, M Timmons, JL Ramdial… - Blood, 2022 - ashpublications.org
Patients with multiple relapsed or refractory (R/R) Hodgkin lymphoma (HL) and other CD30+
lymphoma have few effective therapies available and targeted adoptive natural killer (NK) …
lymphoma have few effective therapies available and targeted adoptive natural killer (NK) …
Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
…, D Chihara, EE Manasanch, JL Ramdial… - Blood …, 2023 - ashpublications.org
Patients with hematologic malignancies have both an increased risk for severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infections and higher morbidity/mortality. They …
syndrome coronavirus 2 (SARS-CoV-2) infections and higher morbidity/mortality. They …
Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality
JL Ramdial, RS Mehta, RM Saliba, AM Alousi… - Bone marrow …, 2021 - nature.com
Despite low nonrelapse mortality (NRM) at day 100 after allogeneic hematopoietic cell
transplantation (HCT), NRM at 1 year remains substantial. In this study, we retrospectively …
transplantation (HCT), NRM at 1 year remains substantial. In this study, we retrospectively …
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance
Standard-of-care for newly-diagnosed, autologous hematopoietic stem cell transplantation (auto-HCT)-eligible,
multiple myeloma (MM) patients includes bortezomib, lenalidomide, and …
multiple myeloma (MM) patients includes bortezomib, lenalidomide, and …
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
…, N Saini, TL Shigle, SA Srour, JL Ramdial… - Blood …, 2023 - ashpublications.org
Traditional conditioning regimens for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) provide suboptimal outcomes, especially for older patients and those …
transplantation (allo-HCT) provide suboptimal outcomes, especially for older patients and those …
Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement
…, N Fowler, J Joseph, J Truxillo, JL Ramdial… - Blood …, 2022 - ashpublications.org
Secondary central nervous system large B-cell lymphoma (SCNSL) is rare, with a generally
poor prognosis. There is limited data about the role of autologous stem cell transplantation (…
poor prognosis. There is limited data about the role of autologous stem cell transplantation (…
[HTML][HTML] ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells
BC Valdez, B Yuan, D Murray, JL Ramdial, U Popat… - Oncotarget, 2024 - ncbi.nlm.nih.gov
ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML treatment.
Its efficacy in hematopoietic stem cell transplantation (HSCT), when combined with other …
Its efficacy in hematopoietic stem cell transplantation (HSCT), when combined with other …
